Zhonghua Wai Ke Za Zhi. 2020 Apr 1;58(4):243-251. doi: 10.3760/cma.j.cn112139-20200106-00014.
In order to improve the overall therapeutic effect of gallbladder cancer in China, Branch of Biliary Surgery, Chinese Surgical Society and Chinese Committee of Biliary Surgeons have formulated the guideline for the diagnosis and treatment of gallbladder carcinoma (2019 edition) . The guideline provided an overview of the evidence on epidemiological risk factors, treatment and follow-up strategies for patients with gallbladder cancer.It also updated the new TNM stage and proposed the clinical classification of gallbladder cancer for the first time. The guideline highlighted the importance of accurate prediction of TNM stage and type of gallbladder cancer based on modern high-quality imaging technology and endoscopic techniques.The idea of comprehensive treatment should be established as the fundamental principle for patients with advanced gallbladder cancer, and a multidisciplinary approach is recommended to make optimal clinical decisions. Standard radical surgical treatment should be delivered by a team of experienced hepato-pancreato-biliary surgeons and pathologists.The combination regimens of chemotherapy, radiotherapy, targeted therapy and immunotherapy for gallbladder cancer have shown promise in improving prognosis. Further research is still needed to confer greater survival benefits to patients with gallbladder cancer.
为提高我国胆囊癌的整体治疗效果,中华医学会外科学分会胆道外科学组和中国医师协会胆道外科医师委员会制定了《胆囊癌诊断和治疗指南(2019版)》。该指南概述了胆囊癌患者流行病学危险因素、治疗及随访策略的相关证据。它还更新了新的TNM分期,并首次提出了胆囊癌的临床分类。该指南强调了基于现代高质量成像技术和内镜技术准确预测胆囊癌TNM分期和类型的重要性。应确立综合治疗理念作为晚期胆囊癌患者的基本原则,建议采用多学科方法做出最佳临床决策。标准的根治性手术治疗应由经验丰富的肝胰胆外科医生和病理科医生团队实施。胆囊癌的化疗、放疗、靶向治疗和免疫治疗联合方案在改善预后方面已显示出前景。仍需进一步研究以给胆囊癌患者带来更大的生存益处。